Skip to main content
SpringerLink
Log in

Non-Hodgkin’s Lymphoma

  • Chapter
  • First Online:
Handbook of Evidence-Based Radiation Oncology

Abstract

Rising in incidence (2008 US incidence 66,120 and mortality 19,160); median age 60–65 years. Causative conditions: Immunodeficiency – congenital (SCID, ataxia telangiectasia), acquired (HIV, organ transplant), autoimmune (Sjogren’s, Hashimoto’s disease, rheumatoid arthritis, systemic lupus erythematosus). Environmental – chemicals (pesticides and solvents). Viral – EBV (Burkitt’s lymphoma and NK/T cell), HTLV-1 (human lymphotrophic virus, type I; adult T-cell leukemia in southern Japan and Caribbean, spread by breastfeeding, sex and blood products), HHV-8 (Kaposi’s sarcoma), HCV (extranodal B-cell NHL). Bacterial – Helicobacter pylori (MALT). Radiation – weak association. Chemo – alkylating agents.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

REFERENCES

  • Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003;362:516-522.

    Article  PubMed  CAS  Google Scholar 

  • Armitage JO. Defining the stages of aggressive non-Hodgkin’s lymphoma – a work in progress. N Engl J Med 2005;352:1250-1252.

    Article  PubMed  CAS  Google Scholar 

  • Ballonoff A, McCammon R, Schwer A, et al. Increased overall survival in patients with stages i and ii diffuse large b-cell lymphoma treated with radiation therapy: a surveillance, epidemiology, and end results (SEER) analysis. Int J Radiat Oncol Biol Phys 2007;69S:S15-S16.

    Article  Google Scholar 

  • Bonnet C, Fillet G, Mounier N, et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2007;25(7):787-792.

    Article  PubMed  CAS  Google Scholar 

  • Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 1997;15:1110–1117.

    CAS  Google Scholar 

  • Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586.

    Article  PubMed  Google Scholar 

  • Coiffier B, Feugier P, Mounier N, et al. Long-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patients. J Clin Oncol 2007;25(suppl 18S):443s. Abstract 8009.

    Google Scholar 

  • Coiffier B, Lepage E, Briere J, et al. CHOP Chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-b-cell lymphoma. N Engl J Med 2002;346:235-242.

    Article  PubMed  CAS  Google Scholar 

  • Feugier P et al. Long-term results of the r-chop study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005;23:4117-4126.

    Article  PubMed  CAS  Google Scholar 

  • Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 1993;328:1002-1006.

    Article  PubMed  CAS  Google Scholar 

  • Guglielmi C, Gomez F, Philip T, Hagenbeek A, Martelli M, Sebban C, et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol 1998;16:3264-3269.

    PubMed  CAS  Google Scholar 

  • Haas R, Poortmans P, de Jong D, et al. High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol 2003;21(13):2474-2480.

    Article  PubMed  CAS  Google Scholar 

  • Habermann T, Weller E, Morrison V, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-3127.

    Article  PubMed  CAS  Google Scholar 

  • Hagenbeek A, Eghbali H, Monfardini S, et al. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage iii and IV low-grade malignant non-Hodgkin’s lymphoma. J Clin Oncol 2006;24:1590-1596.

    Article  PubMed  CAS  Google Scholar 

  • Hancock BW, Qian W, Linch D et al. Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial. Br J Hematol 2009;144(3):367-375.

    Article  CAS  Google Scholar 

  • Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab assed to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome for patient with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German low-grade lymphoma study group. Blood 2005;106:3725-3732.

    Article  PubMed  CAS  Google Scholar 

  • Horning SJ, Weller E, Kim K, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin’s lymphoma: Eastern Cooperative Oncology Group Study 1484. J Clin Oncol 2004;22:3032-3038.

    Article  PubMed  CAS  Google Scholar 

  • Hoster E, Dreyling M, Klapper W et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008;111:558-565.

    Article  PubMed  CAS  Google Scholar 

  • Koch P, Probst A, Berdel WE et al. Treatment results in localized primary gastric lymphoma: data of patients registered within the German Multicenter Study (GIT NHL 02/96). J Clin Oncol 2005;23(28):7050-7059.

    Article  PubMed  Google Scholar 

  • Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996;14:1282-1290.

    PubMed  CAS  Google Scholar 

  • Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared cyclophosphamide, vincristine and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26(28):4579-4586.

    Article  PubMed  CAS  Google Scholar 

  • Miller TP, Dahlberg S, Cassady JR, et al. chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med 1998;339:21-26.

    Article  PubMed  CAS  Google Scholar 

  • Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004;350:1287-1295.

    Article  PubMed  CAS  Google Scholar 

  • Pfreundschuh M, Trümper L, Österborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-391.

    Article  PubMed  CAS  Google Scholar 

  • Morschhauser F, Radford J, Van Hoof A, et al. Phase II trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008;26(32):5156-5164.

    Article  PubMed  CAS  Google Scholar 

  • Park SI, Press OW. Radioimmunotherapy for treatment of B-cell lymphomas and other hematologic malignancies. Curr Opin Hematol 2007;14(6):632-638.

    Article  PubMed  Google Scholar 

  • Petersen PM, Gospodarowicz MK, Tsang RW, et al. Long-term outcome in stage I and II follicular lymphoma following treatment with involved field radiation therapy alone. J Clin Oncol 2004;22:6521.

    Google Scholar 

  • Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9(2):105-116.

    Article  PubMed  CAS  Google Scholar 

  • Pfreundschuh M, Trümper L, Ma D, et al. Randomized intergroup trial of first line treatment for patients <=60 years with diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab – early stopping after the first interim analysis. J Clin Oncol 2004;22:6500.

    Google Scholar 

  • Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 1995;333:1540-1545.

    Article  PubMed  CAS  Google Scholar 

  • Press OW, Unger JM, Braziel RM, et al. Phase II trail of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin’s lymphoma: fiver-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006;24(25):4143-4149.

    Article  PubMed  CAS  Google Scholar 

  • Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 2005;352:1197-1205.

    Article  PubMed  CAS  Google Scholar 

  • Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104(5):1258-1265.

    Article  PubMed  Google Scholar 

  • Spier CM, LeBlanc M, Chase E, et al. Histologic subtypes do not confer unique outcomes in early-stage lymphoma: long-term follow-up of SWOG 8736. Blood 2004;104:abst 3263.

    Google Scholar 

  • Tsukamoto N, Kojima M, Hasegawa M et al. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. Cancer 2007;110(3):652-659.

    Article  PubMed  Google Scholar 

  • Vaughan Hudson B, Vaughan Hudson G, MacLennan KA, et al. Clinical stage 1 non-Hodgkin’s lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. Br J Cancer 1994;69:1088-1093.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Radiation Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada

    Hans T. Chung MD

  2. Radiation Oncology, University of California San Francisco, San Francisco, CA, USA

    Stephen L. Shiao MD, PhD & Naomi R. Schechter MD

Authors
  1. Hans T. Chung MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen L. Shiao MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Naomi R. Schechter MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Div. Radiation Oncology, Oregon Clinic, SW. Barnes Rd. 9205, Portland, 97225, Oregon, USA

    Eric K. Hansen

  2. Department of Radiation Oncology, University of California, San Francisco, Divisadero Street, Suite H-1031 1600, San Francisco, 94143, California, USA

    Mack Roach

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag New York

About this chapter

Cite this chapter

Chung, H.T., Shiao, S.L., Schechter, N.R. (2010). Non-Hodgkin’s Lymphoma. In: Hansen, E., Roach, M. (eds) Handbook of Evidence-Based Radiation Oncology. Springer, New York, NY. https://doi.org/10.1007/978-0-387-92988-0_36

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-92988-0_36

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-92987-3

  • Online ISBN: 978-0-387-92988-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation